Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - January 2013

 

Expertise in Neuropharmacology


Winter News

2012 Consulting assignments completed

NeuroAct Communication carried out a variety of consulting assignments in 2012 for diverse pharmaceutical companies and market research agencies. For more information see Consulting Services.

International Serotonin Research Society (ISRS)

The ISRS (formerly known as the Serotonin Club) is renewing its Council membership and elected Adrian Newman-Tancredi as one of its European representatives: he will take up his responsibilities on the Council as of January 2013. Adrian has been a long-standing member of the Serotonin Club and has published extensively on the pharmacology of serotonergic drugs, such as antidepressants and antipsychotics (see Publications).

University lectures

Adrian has recently given lectures at the Universities of Groningen, Netherlands (8 Nov. 2012), Lyon, France (15 Nov. 2012) and Lund, Sweden (10 Dec. 2012).
The lectures focused on novel pharmacotherapeutic treatments for depressive disorders and Parkinson's disease.

For more information on Adrian's lectures and neuropharmacology expertise: Consulting services.

 

 

 

  

Serotonin Club

 

 

  

 

 

 

 

 

 

Adrian Newman-Tancredi is co-founder and Chief Scientific Officer of Neurolixis Inc., a CNS drug discovery and development start-up. Neurolixis is advancing its program of in-licensing clinical assets and synthesis of Novel Chemical Entities.

Neurolixis is currently aquiring financing from investors and grant-awarding institutions to support its drug discovery and early development projects. For further information or to make an investment, Contact.

 

NeuroAct Communication has had another successful year of neuropharmacology and drug discovery consulting:
thank you and we look forward to working with you in 2013 !

 

 
Scientific Communication

ECNP Symposium presentation:

 

Adrian presented at a symposium of the 25th European College of Neuropsychopharmacology (ECNP) in Vienna, Austria, on 15 October 2012. The symposium was entitled "New mechanisms and novel therapeutics: how recent discoveries are opening perspectives for targeting serotonin 5-HT1A receptor function." Adrian's lecture focused on novel drugs exhibiting biased agonism. For details of the symposium click here.

ECNP Congress participants can access a Webcast of the lecture.

  

 

NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.  

 

NeuroAct Communication is an independent consulting service founded by
Adrian Newman-Tancredi Ph.D., an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile